These results are not final. However, it's not enough to fear the BHF and Gilbert Dupont Pride at an early stage.
The last one states that the 48-week delay is too early to assess the therapeutic benefit of GS010 reliably.
The broker identifies two reasons. The first is that genetic therapy has not been sufficiently established to achieve its full potential.
The second is that tissue deterioration – and thus from visual disturbance – is still under way, which does not allow to visualize benefit provided that the low point (neir) is not reached. Achieving this low point is between 3 and 5 months, and after that the downturn is stabilized in anatomical and visual terms.
The broker waited for the reaction of the decline in the title following this announcement.
However, it still remains a price with a target price of € 9 on the title. The consultant company is waiting for Reverse (patients treated between 6 and 12 months after diagnosis), 96 weeks and 96 mile rescue will be the milestones that will reveal the true potential of therapy whose trends are Positively observed 72 weeks This is an inverse Framework that is an inverse framework.
Oddo BHF has also confirmed its recommendation for Buying and a target price of € 6.10 on Gensight.
The broker reminds us that "we are talking here of evolutionary pathology". Also the real benefit is the results 72 and 96 weeks.
Clinical Trials (Steps To, II, III)
Step 1: people on small scale molecule testing to evaluate its safety, tolerance, its metabolic and pharmacological features. Stage II: evaluate the tolerance and effectiveness of several hundred patients to identify secondary effects. III: an assessment of the overall benefit / risk ratio for several thousand patients.
Copyright 2019 AOF
All reproduction rights and representation held (Legal notice)